Prospecto: information for the user
Vizarsin 100 mg buccal dispersible tablets
sildenafil
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
Vizarsin contains the active ingredient sildenafilo, which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by dilating the blood vessels in the penis, allowing blood to flow when sexually stimulated. Vizarsin will only help you achieve an erection if you are sexually stimulated.
Vizarsin is indicated for the treatment of erectile dysfunction in adult men, sometimes referred to as impotence. This occurs when a man is unable to obtain or maintain a firm, adequate erection for satisfactory sexual activity.
Do not take Vizarsin
Warnings and precautions
Consult your doctor or pharmacist before starting to take Vizarsin:
It is not recommended to use Vizarsin simultaneously with any other oral or local treatment for erectile dysfunction.
Do not take Vizarsin with treatments for pulmonary arterial hypertension (PAH) that contain sildenafil or any other PDE5 inhibitor.
Do not take Vizarsin if you do not have erectile dysfunction.
The use of Vizarsin is not indicated in women.
Special considerations in patients with renal or hepatic problems
You must inform your doctor if you have renal or hepatic problems. Your doctor may decide to reduce your dose.
Children and adolescents
The use of Vizarsin is not indicated in individuals under 18 years old.
Use of Vizarsin with other medications
Consult your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Vizarsin may interact with some medications, especially those used to treat chest pain. In case of a medical emergency, you must inform your doctor, pharmacist, or nurse that you are taking Vizarsin and when you took it. Do not take Vizarsin with other medications unless your doctor advises you to.
Do not take Vizarsin if you are taking medications called nitrates, as the combination of these medications may lead to a dangerous drop in your blood pressure. Always inform your doctor, pharmacist, or nurse if you are taking any of these medications, which are often used to relieve chest pain (or "chest pain").
Do not take Vizarsin if you are taking medications called nitric oxide donors, such as amyl nitrite ("poppers"), as the combination may also lead to a dangerous drop in your blood pressure.
Inform your doctor or pharmacist if you are taking riociguat.
If you are taking medications known as protease inhibitors, such as those used to treat HIV, your doctor may recommend that you start treatment with the lowest dose (25 mg) of Vizarsin.
Some patients taking an alpha-blocker, a medication used to treat high blood pressure or prostate enlargement, may experience dizziness or lightheadedness caused by a drop in blood pressure when sitting or standing up quickly. Some patients have experienced these symptoms when taking Vizarsin with alpha-blockers. This is more likely to occur within 4 hours after taking Vizarsin. To reduce the likelihood of these symptoms, you should be receiving your daily dose of the alpha-blocker regularly before starting Vizarsin. Your doctor may recommend that you start treatment with the lower dose (25 mg) of Vizarsin.
Use of Vizarsin with food, drinks, and alcohol
Vizarsin can be taken with or without food. However, you may notice that Vizarsin takes a little longer to take effect if taken with a large meal. You should have an empty mouth before taking the tablet.
Consuming alcohol may temporarily impair your ability to achieve an erection. Therefore, to get the maximum benefit from the medication, it is recommended not to consume large amounts of alcohol before taking Vizarsin.
Pregnancy, breastfeeding, and fertility
The use of Vizarsin is not indicated in women.
Driving and operating machinery
Vizarsin may cause dizziness and affect your vision. You should know how you react to Vizarsin before driving vehicles or operating machinery.
Vizarsin contains aspartame (E951) and sucrose
This medication contains 1.5 mg of aspartame in each buccal dispersible tablet. Aspartame contains a source of phenylalanine that may be harmful in cases of phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it correctly.
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended starting dose is 50 mg.
Do not take Vizarsin more than once a day.
Do not take Vizarsin buccal tablets at the same time as other presentations of Vizarsin.
You should take Vizarsin approximately one hour before planning to have sexual intercourse.
Vizarsin tablets are fragile. Do not push them through the blister packaging because
they may break. Do not handle the tablets with wet hands, as they may break. To remove a tablet, follow these steps:
For blisters of 1 tablet:
For blisters of 4 tablets:
In a few seconds, it will begin to disintegrate in the mouth, so it can be taken with or without water.
You should have an empty mouth before placing the tablet on the tongue.
If you notice that the action of Vizarsin is too strong or too weak, inform your doctor or pharmacist.
Vizarsin will only help you achieve an erection if you are sexually stimulated. The time it takes for Vizarsin to take effect varies from person to person, usually ranging from half an hour to one hour. The effect of Vizarsin may be delayed if taken with a large meal.
If Vizarsin does not help you achieve an erection or if the erection does not last long enough to complete sexual intercourse, consult your doctor.
If you take more Vizarsin than you should
You may experience an increase in adverse effects and their severity. Doses above 100 mg do not increase efficacy.
Do not take more tablets than recommended by your doctor.
Contact your doctor if you have taken more tablets than advised.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. The side effects reported associated with the use of Vizarsin are generally of mild to moderate intensity and short duration.
If you experience any of the following serious side effects, stop taking Vizarsin and seek medical attention immediately:
The symptoms include sudden hissing when breathing, difficulty breathing or dizziness, swelling of the eyelids, face, lips, or throat.
If they occur during or after sexual intercourse:
If you have an erection that lasts more than 4 hours, you must contact your doctor immediately.
The symptoms may include severe peeling and swelling of the skin, vesiculation of the mouth, genitals, and around the eyes, as well as fever.
Other side effects:
Very common(may affect more than 1 in 10 people): headache.
Common(may affect up to 1 in 10 people): nausea, facial flushing,heat sensation (including sudden feeling of heat in the upper body), indigestion, abnormal color perception, blurred vision, visual deterioration, nasal congestion, and dizziness.
Uncommon(may affect up to 1 in 100 people): vomiting, skin rash,eye irritation, eye discharge/red eyes, eye pain, flashing lights, visual clarity, light sensitivity, watery eyes, palpitations, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling of drowsiness, reduced tactile sensation, vertigo, ringing in the ears, dry mouth, nasal congestion or blockage, nasal mucosa inflammation (including symptoms such as runny nose, sneezing, and nasal congestion), upper abdominal pain, gastroesophageal reflux disease (including symptoms such as heartburn), blood in urine, arm or leg pain, nasal bleeding, feeling of heat, and feeling tired.
Rare(may affect up to 1 in 1,000 people): fainting, stroke,heart attack, irregular heartbeat, transient decrease in blood flow to some parts of the brain, sensation of throat constriction, numbness of the mouth, bleeding in the back of the eye, double vision, visual acuity decrease, abnormal sensation in the eye, eye swelling or eyelid swelling, small particles or spots in vision, halos around lights, pupil dilation, change in color of the white part of the eye, bleeding from the penis, blood in semen, dry nose, nasal swelling, feeling of irritability, and sudden decrease or loss of hearing.
During post-marketing experience, rare cases of unstable angina (heart disease) and sudden death have been reported. It is worth noting that most men who experienced these side effects, although not all of them, had heart problems before taking this medicine. It is not possible to determine if these side effects were directly related to Vizarsin.
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly throughthe national notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blister pack after EXP. The expiration date is the last day of the month indicated.
Do not store above 30?°C.
Store in the original packaging to protect it from moisture.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medication that you no longer need. This will help protect the environment.
Composition of Vizarsin
See section 2 “Vizarsin contains aspartame (E951) and sucrose”.
Appearance of the product and contents of the pack
White or off-white, round, biconvex tablets, which may have darker spots.
Vizarsin buccal tablets are available in packs of 1 buccal tablet in a blister pack and also in packs of 2 x 1, 4 x 1, 8 x 1, 12 x 1 or 24 x 1 buccal tablets in perforated unit dose blisters.
Only some pack sizes may be marketed.
Marketing Authorization Holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturers
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/BelgienLietuva
KRKA Belgium, SA.UAB KRKA Lietuva
Phone: +32 (0) 487 50 73 62Phone: + 370 5 236 27 40
????????Luxembourg/Luxemburg
???? ???????? ????KRKA Belgium, SA.
Phone: + 359 (02) 962 34 50Phone: +32 (0) 487 50 73 62 (BE)
Czech RepublicMagyarország
KRKA CR, s.r.o.KRKA Magyarország Kereskedelmi Kft.
Phone: + 420 (0) 221 115 150Phone: + 36 (1)355 8490
DenmarkMalta
KRKA Sverige ABE. J. Busuttil Ltd.
Phone: + 46 (0)8 643 67 66 (SE)Phone: + 356 21 445 885
GermanyNetherlands
TAD Pharma GmbHKRKA Belgium, SA.
Phone: + 49 (0) 4721 606-0Phone: +32 (0) 487 50 73 62 (BE)
EstoniaNorway
KRKA, d.d., Novo mesto Eesti filiaalKRKA Sverige AB
Phone: + 372 (0) 6 671 658Phone: + 46 (0)8 643 67 66 (SE)
GreeceAustria
KRKA ΕΛΛΑΣ ΕΠΕKRKA Pharma GmbH, Wien
Phone: + 30 2100101613Phone: + 43 (0)1 66 24 300
SpainPoland
KERN PHARMA, S.L.KRKA-POLSKA Sp. z o.o.
Phone: + 34 93 700 25 25Phone: + 48 (0)22 573 7500
FrancePortugal
KRKA France EurlKRKA Farmacêutica, Sociedade Unipessoal Lda.
Phone: + 33 (0)1 57 40 82 25Phone: + 351 (0)21 46 43 650
CroatiaRomania
KRKA - FARMA d.o.o.KRKA Romania S.R.L., Bucharest
Phone: + 385 1 6312 100Phone: + 4 021 310 66 05
IrelandSlovenia
KRKA Pharma Dublin, Ltd.KRKA, d.d., Novo mesto
Phone: + 353 1 293 91 80Phone: + 386 (0) 1 47 51 100
IcelandSlovakia
LYFIS ehf.KRKA Slovensko, s.r.o.
Phone: + 354 534 3500Phone: + 421 (0) 2 571 04 501
ItalyFinland
KRKA Farmaceutici Milano S.r.l.KRKA Finland Oy
Phone: + 39 02 3300 8841Phone: +358 20 754 5330
CyprusSweden
KI.PA. (PHARMACAL) LIMITEDKRKA Sverige AB
Phone: + 357 24 651 882Phone: + 46 (0)8 643 67 66 (SE)
LithuaniaUnited Kingdom
KRKA Latvija SIAConsilient Health (UK) Ltd.
Phone: + 371 6 733 86 10Phone: + 44(0)203 751 1888
Last date of revision of the summary of product characteristics:
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.